ESPERION THERAPEUTICS INC (ESPR:NASDAQ)
$3.13 0.01 (0.3205%)
Analysed ESPERION THERAPEUTICS INC (ESPR:NASDAQ) News Sources
Esperion Therapeutics (ESPR) Down 10% Since Last Earnings Report: Can It Rebound?
09-04-2026
yahoo.com
Esperion Therapeutics Highlights 38% Revenue Growth, Enbumyst Launch Plan at Needham Conference
13-04-2026
marketbeat.com
Esperion to Report First Quarter 2026 Financial Results on May 7
23-04-2026
yahoo.com
Esperion to be Acquired by ARCHIMED
01-05-2026
yahoo.com
Summit’s ‘self-inflicted’ stumble; Esperion’s take-private deal
01-05-2026
biopharmadive.com
ARCHIMED to acquire Esperion Therapeutics in $1.1 billion deal
01-05-2026
qz.com
Esperion Announces Two New Analyses Supporting Bempedoic Acid to Reduce LDL-C Levels to be Presented at the European Atherosclerosis Society (EAS) Congress 2026
13-05-2026
yahoo.com
ESPR Stock Surges 44% in a Month: Here's What You Need to Know
14-05-2026
yahoo.com
Esperion Announces Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)
14-05-2026
yahoo.com
Esperion Presents New Data from CLEAR Outcomes and the CLEAR PATH Phase 2 Pediatric Study at the European Atherosclerosis Society Congress 2026
26-05-2026
yahoo.com
What is the current price of ESPERION THERAPEUTICS INC (ESPR:NASDAQ)?
The current price of ESPERION THERAPEUTICS INC (ESPR:NASDAQ) is $3.13.
ESPERION THERAPEUTICS INC (ESPR:NASDAQ) absolute price change since previous trading day?
The absolute price change of ESPERION THERAPEUTICS INC (ESPR:NASDAQ) since the previous trading day is $0.01.
ESPERION THERAPEUTICS INC (ESPR:NASDAQ) percentage price change since previous trading day?
The percentage price change of ESPERION THERAPEUTICS INC (ESPR:NASDAQ) since the previous trading day is 0.3205%.
What is the most recent average sentiment score for ESPERION THERAPEUTICS INC (ESPR:NASDAQ)?
The most recent average sentiment score for ESPERION THERAPEUTICS INC (ESPR:NASDAQ) is 72 out of 100.
What is the most recent average sentiment for ESPERION THERAPEUTICS INC (ESPR:NASDAQ)?
The most recent sentiment for ESPERION THERAPEUTICS INC (ESPR:NASDAQ) is .
SEC-8K** Filing Available For ESPERION THERAPEUTICS INC (ESPR:NASDAQ)
** material developments that could impact a company's financial condition or stock price.
Author: MattELab
MattELab is the founder and lead developer of SentientMerchant. With a Computer Science and Quantitative Finance background from a T10 university, he brings over 6 years of expertise in NLP, programmatic SEO, and full-stack development to build highly scalable AI and FinTech solutions.